Masayuki Kuraoka

Masayuki Kuraoka

Auto-generated profile, based on publicly available information

Masayuki Kuraoka

Duke University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Cell Host & Microbe
Verified
Journal Article
Closed access
GBGoran Bajic
Goran Bajic
MMMax J. Maron
Max J. Maron
YAYu Adachi
Yu Adachi
TOTaishi Onodera
Taishi Onodera
KMKevin R. McCarthy
Kevin R. McCarthy
ASAaron G. Schmidt
Aaron G. Schmidt

6 May 2022 in Science Immunology
Verified
Journal Article
Closed access
MKMasayuki Kuraoka
Masayuki Kuraoka
CYChen-Hao Yeh
Chen-Hao Yeh
GBGoran Bajic
Goran Bajic
RKRyutaro Kotaki
Ryutaro Kotaki
SSShengli Song
Shengli Song
GKGarnett Kelsoe
Garnett Kelsoe
Immunization or microbial infection can establish long-term B cell memory not only systemically but also locally. Evidence has suggested that local B cell memory contributes to early local plasmacytic responses after secondary challenge. However, it is unclear whether locality of immunization plays any role in memory B cell participation in recall germinal centers (GCs), which is essential for updating their B cell antigen receptors (BCRs). Using single B cell culture and fate mapping, we have characterized BCR repertoires in recall GCs after boost immunizations at sites local or distal to the priming. Local boosts with homologous antigen recruit the progeny of primary GC B cells to recall GCs more efficiently than do distal boosts. Recall GCs elicited by local boosts contain significantly more B cells with elevated levels of immunoglobulin (Ig) mutation and higher avidity BCRs. This local preference is unaffected by blocking CD40:CD154 interaction to terminate active, GC responses. Local boosts with heterologous antigens elicit secondary GCs with B cell populations enriched for cross-reactivity to the prime and boost antigens; in contrast, cross-reactive GC B cells are rare after distal boosts. Our results suggest that local B cell memory is retained in the form of memory B cells, GC B cells, and GC phenotype B cells that are independent of organized GC structures and that these persistent “primed B cells” contribute to recall GC responses at local sites. Our findings indicate the importance of locality in humoral immunity and inform serial vaccination strategies for evolving viruses.

16 May 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
AWAkiko Watanabe
Akiko Watanabe
KSKuei-Ying Su
Kuei-Ying Su
MKMasayuki Kuraoka
Masayuki Kuraoka
GYGuang Yang
Guang Yang
ARAlexander E. Reynolds
Alexander E. Reynolds
GKGarnett Kelsoe
Garnett Kelsoe
Immunological tolerance removes or inactivates self-reactive B cells, including those that also recognize cross-reactive foreign antigens. Whereas a few microbial pathogens exploit these “holes” in the B cell repertoire by mimicking host antigens to evade immune surveillance, the extent to which tolerance reduces the B cell repertoire to foreign antigens is unknown. Here, we use single-cell cultures to determine the repertoires of human B cell antigen receptors (BCRs) before (transitional B cells) and after (mature B cells) the second B cell tolerance checkpoint in both healthy donors and in patients with systemic lupus erythematosus (SLE) . In healthy donors, the majority (~70%) of transitional B cells that recognize foreign antigens also bind human self-antigens (foreign+self), and peripheral tolerance halves the frequency of foreign+self-reactive mature B cells. In contrast, in SLE patients who are defective in the second tolerance checkpoint, frequencies of foreign+self-reactive B cells remain unchanged during maturation of transitional to mature B cells. Patterns of foreign+self-reactivity among mature B cells from healthy donors differ from those of SLE patients. We propose that immune tolerance significantly reduces the scope of the BCR repertoire to microbial pathogens and that cross-reactivity between foreign and self epitopes may be more common than previously appreciated.

1 February 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMasayuki Kuraoka
Masayuki Kuraoka
CAClare Burn Aschner
Clare Burn Aschner
IWIan W. Windsor
Ian W. Windsor
AMAakash Mahant Mahant
Aakash Mahant Mahant
SGScott J. Garforth
Scott J. Garforth
BHBetsy C. Herold
Betsy C. Herold
There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on neutralizing antibodies, but for HSV this strategy has proven ineffective. Preclinical studies with a candidate HSV vaccine strain, ΔgD-2, demonstrated that non-neutralizing antibodies that activate Fcγ receptors (FcγRs) to mediate antibody-dependent cellular cytotoxicity (ADCC) provide active and passive protection against HSV-1 and HSV-2. We hypothesized that this vaccine provides a tool to identify and characterize protective mAbs. We isolated HSV-specific mAbs from germinal center and memory B cells and bone marrow plasmacytes of ΔgD-2–vaccinated mice and evaluated these mAbs for binding, neutralizing, and FcγR-activating activity and for protective efficacy in mice. The most potent protective mAb, BMPC-23, was not neutralizing but activated murine FcγRIV, a biomarker of ADCC. The cryo–electron microscopic structure of the Fab–glycoprotein B (gB) assembly identified domain IV of gB as the epitope. A single dose of BMPC-23 administered 24 hours before or after viral challenge provided significant protection when configured as mouse IgG2c and protected mice expressing human FcγRIII when engineered as a human IgG1. These results highlight the importance of FcR-activating antibodies in protecting against HSV.

1 November 2013 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
LMLaurie McWilliams
Laurie McWilliams
KSKuei-Ying Su
Kuei-Ying Su
XLXiaoe Liang
Xiaoe Liang
DLDongmei Liao
Dongmei Liao
SFSerina Floyd
Serina Floyd
MKMasayuki Kuraoka
Masayuki Kuraoka
CD27, a member of the TNFR superfamily, is used to identify human memory B cells. Nonetheless, CD27+ B cells are present in patients with HIGM1 syndrome who are unable to generate GCs or memory B cells. CD27+IgD+ fetal B cells are present in umbilical cord blood, and CD27 may also be a marker of the human B1-like B cells. To define the origin of naïve CD27+IgD+ human B cells, we studied B cell development in both fetal and adult tissues. In human FL, most CD19+ cells coexpressed CD10, a marker of human developing B cells. Some CD19+CD10+ B cells expressed CD27, and these fetal CD27+ cells were present in the pro-B, pre-B, and immature/transitional B cell compartments. Lower frequencies of phenotypically identical cells were also identified in adult BM. CD27+ pro-B, pre-B, and immature/transitional B cells expressed recombination activating gene-1, terminal deoxynucleotidyl transferase and Vpre-B mRNA comparably to their CD27− counterparts. CD27+ and CD27− developing B cells showed similar Ig heavy chain gene usage with low levels of mutations, suggesting that CD27+ developing B cells are distinct from mutated memory B cells. Despite these similarities, CD27+ developing B cells differed from CD27− developing B cells by their increased expression of LIN28B, a transcription factor associated with the fetal lymphoid lineages of mice. Furthermore, CD27+ pro-B cells efficiently generated IgM+IgD+ immature/transitional B cells in vitro. Our observations suggest that CD27 expression during B cell development identifies a physiologic state or lineage for human B cell development distinct from the memory B cell compartment.

7 December 2010 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
MKMasayuki Kuraoka
Masayuki Kuraoka
LMLaurie McWilliams
Laurie McWilliams
GKGarnett Kelsoe
Garnett Kelsoe